Palatin Technologies Announces First Quarter GAAP EPS of -$0. 86, Beating Estimates by $0. 34

Trending News 🌧️

Palatin Technologies ($NYSEAM:PTN) Inc. is a biopharmaceutical company that develops innovative therapies to treat various medical conditions. The company’s most recent development is a treatment for erectile dysfunction. Palatin Technologies Inc. announced today that their first quarter GAAP EPS of -$0. 34.

This is good news for the company, as it shows that their new treatment is having positive results. Palatin Technologies Inc. is confident that their new treatment will help many men suffering from erectile dysfunction.

Earnings

34. In its earning report of FY2022 Q4 as of June 30, Palatin Technologies earned 1.5M USD in total revenue and lost 36.2M USD in net income. Compared to the previous year, there was an 850.0% decrease in total revenue. However, Palatin Technologies’s total revenue still managed to reach 1.5M USD in the last 3 years.

Price History

34. The company’s stock opened at $4.6 and closed at $4.3, a drop of 7.7% from the previous day’s close of $4.7. Despite the drop in stock price, the company’s quarterly results were better than expected, with EPS coming in above analyst estimates.

VI Analysis

PALATIN TECHNOLOGIES is a company with strong fundamentals and long-term potential.

However, it is important to note that the company has an intermediate health score of 5/10 with regard to its cashflows and debt. This means that the company may have some difficulty paying off its debt and funding future operations. PALATIN TECHNOLOGIES is strong in terms of assets, but only medium in terms of profitability and weak in terms of dividend and growth. The company is classified as an ‘elephant’, which means that it is a large company with a lot of assets after deducting liabilities. PALATIN TECHNOLOGIES is a company that may be of interest to investors who are looking for a company with strong fundamentals and long-term potential.

VI Peers

The company’s products are based on its proprietary technology platforms, which enable the targeted delivery of biologic and small molecule drugs. Palatin’s lead product candidates are VEN307, a topical gel for the treatment of acne vulgaris, and Rekkerd, a next-generation oral direct thrombin inhibitor. Palatin is also developing a portfolio of other product candidates for the treatment of various indications, including psoriasis, rosacea, and erectile dysfunction. The company’s competitors include OncoSec Medical Inc, Ember Therapeutics Inc, and Vaxxinity Inc.

– OncoSec Medical Inc ($NASDAQ:ONCS)

OncoSec Medical Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel cancer therapeutics. The company’s product candidates include TAVO, a T-cell therapy for the treatment of solid tumors, and KEYTRUDA, an anti-PD-1 antibody for the treatment of melanoma. OncoSec Medical Inc has a market cap of 7.52M as of 2022, a Return on Equity of -234.25%. The company’s product candidates are currently in clinical trials and have not yet been approved for commercial use.

– Ember Therapeutics Inc ($OTCPK:EMBT)

Ember Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases. The company’s lead drug candidate is EBT-101, a first-in-class, orally available small molecule that is in development for the treatment of non-alcoholic steatohepatitis (NASH). Ember Therapeutics Inc has a market cap of 926.88k as of 2022 and a Return on Equity of 3.46%. The company’s focus on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases makes it a promising player in the healthcare industry.

– Vaxxinity Inc ($NASDAQ:VAXX)

Vaxxinity Inc is a clinical-stage biotechnology company focused on the development and commercialization of next-generation vaccines. The company has a market cap of 205.47M as of 2022 and a return on equity of -67.46%. The company’s lead product candidate is a novel vaccine platform called PENNVAX, which is based on a proprietary chimeric virus technology. PENNVAX is currently in clinical trials for the prevention of influenza and other infectious diseases.

Summary

PALATIN TECHNOLOGIES is a clinical-stage biopharmaceutical company that focuses on the development of targeted, small-molecule drugs to treat cardiovascular, metabolic, and inflammatory diseases.